Curis, Inc. (CRIS)

14.85 +0.54 (+3.77%) At close: 04:00PM EDT

Curis, Inc.

Building C
Suite 500 128 Spring Street
Lexington, MA 02421
United States
617 503 6500
https://www.curis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 49

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James E. Dentzer	President, CEO, Secretary, Treasurer & Director	1.07M	N/A	1967
Ms. Diantha Duvall CPA, M.B.A.	CFO and Principal Financial & Accounting Officer	719.02k	N/A	1972
Dr. Jonathan B. Zung Ph.D.	Chief Development Officer	691.27k	N/A	1966
Mr. Mark W. Noel	Vice President of Technology Management & Intellectual Property	279.28k	85.7k	1959
Ms. Elif McDonald	VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Reinhard Wilhelm von Roemeling M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Corporate governance

Curis, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.